VANCOUVER, British Columbia, May 17, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that its shares will commence trading on the OTCQB ® Venture Market (the “OTCQB”) on May 17, 2021…


Previous articleMindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial
Next articleIntelGenx Announces Initial Closing of atai Investment